LEERINK PARTNERS

Dupixent® for COPD Delivers Across the Board

Published on: January 07, 2025

> GCEA suggests Dupixent’s societal benefits for COPD should outweigh its cost even at US market-based pricing over the exclusivity period

Based on our societal impact analysis, we anticipate that Dupixent for COPD will have a positive impact on all 24 value elements. Patients living with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype now have a new treatment option. The U.S. Food and Drug Administration approved dupilumab (Dupixent®, Regeneron and Sanofi) on September 27th, 2024.

For individuals living with inadequately controlled COPD and an eosinophilic phenotype, Dupixent is expected to result in fewer exacerbations, longer length of life, better quality of life, less uncertainty in health outcomes, and more labor and non-labor productivity. For caregivers, Dupixent is expected to result in less time caregiving and positive impacts on a caregiver's quality of life. For the health system, Dupixent is expected to reduce costs associated with exacerbations. And for society, we now have a new treatment option for COPD that may result in scientific spillovers and future biosimilars offering value to society long after its branded period.

Our generalized cost-effectiveness analysis suggests Dupixent's societal benefits should outweigh its US cost (even at US market-based pricing over the exclusivity period) for COPD.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:

Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm's research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm's market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109.MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.
Member FINRA/SIPC